EcoDrugPlus

Nischarin

Ensembl ID : ENSOKIG00005018720
Gene Symbol: NISCH
3 Cross references
207 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSOKIG00005017538
Gene Symbol: NOS2
3 Cross references
159 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSOKIG00005006205
Gene Symbol: NOS2
1 Cross references
160 Possible Orthologues:

Nociceptin Receptor

Ensembl ID : ENSOKIG00005040659
Gene Symbol: LOC109869426
3 Cross references
185 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSOKIG00005014728
Gene Symbol: NOTCH1
3 Cross references
196 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSOKIG00005000726
Gene Symbol: NOTCH1
3 Cross references
192 Possible Orthologues:

Nuclear Factor Nf-Kappa-B P105 Subunit

Ensembl ID : ENSOKIG00005026011
Gene Symbol: LOC109864709
2 Cross references
194 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2

Ensembl ID : ENSOKIG00005035115
Gene Symbol: LOC109870785
3 Cross references
199 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2

Ensembl ID : ENSOKIG00005028699
Gene Symbol: LOC109866904
3 Cross references
199 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2

Ensembl ID : ENSOKIG00005029608
Gene Symbol: LOC109890738
2 Cross references
203 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSOKIG00005007543
Gene Symbol: NFKB1
3 Cross references
194 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSOKIG00005019181
Gene Symbol: NR1H3
1 Cross references
385 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).